Back to Peptides
PT-141 (Bremelanotide) vs Melanotan II
Sexual FunctionPT-141 is derived from Melanotan II but refined for sexual function only. PT-141 (Vyleesi) is FDA-approved for female HSDD and selectively targets MC3R/MC4R for libido enhancement without skin tanning. Melanotan II is a broader melanocortin agonist that tans skin AND enhances libido as a side effect. PT-141 is the targeted, regulated option; Melanotan II is the multi-effect research peptide.
high Search Demand
Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | Melanotan II |
|---|---|---|
| dosing | 1.75 mg SubQ 45 min before activity (max 1 dose/24h, max 8 doses/month) | 250-500 mcg SubQ daily during loading, then 1-2x weekly maintenance |
| best for | Sexual dysfunction (HSDD in women, ED in men), targeted libido enhancement | UV-free tanning with libido enhancement as bonus effect |
| mechanism | Selective MC3R/MC4R agonist — enhances libido and arousal through central nervous system pathways | Non-selective melanocortin agonist (MC1-5R) — stimulates melanin production AND sexual arousal |
| fda status | FDA-approved (Vyleesi) for HSDD in premenopausal women | Not FDA-approved; research peptide with no regulatory approval anywhere |
| side effects | Nausea (40%), flushing, headache, transient hypertension | Nausea, facial flushing, appetite suppression, mole darkening, spontaneous erections |
| tanning effect | None — does not affect melanin or skin pigmentation | Significant — produces noticeable darkening within 1-2 weeks |
Verdict
PT-141 for targeted sexual function support with FDA backing. Melanotan II if tanning is also desired. PT-141 is the safer, more studied option. Melanotan II carries additional risks from broad melanocortin activation.